Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR-KO screening to identify resistance/sensitation to PI3Kb+MCL1 inhibition in PTEN-null breast cancer cell line EVSA-T

ABSTRACT: CRISPR-KO screening to identify resistance/sensitation to PI3Kb and MCL1 combinatorial inhibition in PTEN-null breast cancer cell line, EVSA-T

SUBMITTER: Kosuke Yusa

PROVIDER: S-BSST190 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

CRISPR-KO screening to identify resistance/sensitation to PI3K pathway inhibition in PTEN-null breast cancer cell lines

Project description: Not available

| S-BSST189 | biostudies-other

AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.

Project description: Not available

| S-EPMC8488980 | biostudies-literature

Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer.

Project description: Not available

| S-EPMC4304881 | biostudies-literature

USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.

Project description: Not available

| S-EPMC12618074 | biostudies-literature

Untargeted stable isotope-resolved metabolomics to assess the effect of PI3Kβ inhibition on metabolic pathway activities in a PTEN null breast cancer cell line.

Project description: Not available

| S-EPMC9614656 | biostudies-literature

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

Project description:KRAS inhibitors (KRASi) targeting various KRAS mutations have entered clinical trials for pancreatic cancer. Despite promising preliminary clinical responses, most patients relapse due to intrinsic and acquired resistance. Thus, combination treatments are essential to extend the efficacy of KRAS-targeted therapies. To further determine genetic mechanisms of KRASi resistance, we performed KRASi-anchored CRISPR-Cas9 loss-of-function screens in KRAS G12D-, KRAS G12R-, and KRAS Q61H-mutant PDAC cell lines, using six KRASi, to identify genes, that when lost, modulate sensitivity to KRAS inhibition. We pharmacologically validated several hits from our screens, including EGFR, CK2 p110 alpha and p110 gamma, and YAP, by combining targeted inhibitors with KRASi. We determined that KRAS Q61H-mutant PDAC cell lines are intrinsically less dependent on KRAS for survival than other KRAS mutational subtypes. Further, we found that EGFR inhibitor erlotinib synergized with the RAS(ON) multi-selective inhibitor RMC-7977 in KRAS Q61H-mutant PDAC cell lines, and in cell lines with highly active EGFR, by mitigating ERK rebound activity. We also developed KRASi-resistant cell lines and observed sustained ERK MAPK dependence in the KRASi-resistant cell lines despite decreased ERK activity. Our findings enhance the understanding of KRASi intrinsic and acquired resistance and identify therapeutic vulnerabilities that can potentially be exploited for KRASi combination therapies in patients with PDAC.

2025-11-27 | GSE310675 | GEO

CRISPR screens identify gene targets at breast cancer risk loci.

Project description: Not available

| S-EPMC10053147 | biostudies-literature

Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.

Project description: Not available

| S-EPMC7411640 | biostudies-literature

CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer.

Project description: Not available

| S-EPMC12691371 | biostudies-literature

Targeting of GPCR and EGF receptor overcomes PI3K inhibitor resistance in PTEN-null breast cancer

Project description: Not available